Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pfizer to acquire Coley

COLY jumped $4.81 (160%) to $7.81 on Friday after PFE said it will acquire the biotech for $8 per share in cash. The deal values COLY at $230 million,

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE